1921
Volume 102, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

There is no abstract available for this article.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.20-0271
2020-04-16
2020-10-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/6/tpmd200271.html?itemId=/content/journals/10.4269/ajtmh.20-0271&mimeType=html&fmt=ahah

References

  1. Omura S, Crump A, 2014. Ivermectin: panacea for resource-poor communities? Trends Parasitol 30: 445455.
    [Google Scholar]
  2. The Ivermectin Roadmappers, 2020. A roadmap for the development of ivermectin as a complementary malaria vector control tool. Am J Trop Med Hyg 102: 324.
    [Google Scholar]
  3. Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C Vasudevan SG, Jans DA, 2013. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res 99: 301306.
    [Google Scholar]
  4. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA, 2020. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res 177: 104760.
    [Google Scholar]
  5. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA, 2012. Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J 443: 851856.
    [Google Scholar]
  6. Barrows NJ et al., 2016. A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20: 259270.
    [Google Scholar]
  7. Varghese FS, Kaukinen P, Glasker S, Bespalov M, Hanski L, Wennerberg K Kümmerer BM, Ahola T 2016. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res 126: 117124.
    [Google Scholar]
  8. Mastrangelo E et al., 2012. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67: 18841894.
    [Google Scholar]
  9. Lee YJ, Lee C, 2016. Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Arch Virol 161: 257268.
    [Google Scholar]
  10. Caly L, Druce J, Catton M, Jans D, KM W, 2020. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. Available at: https://www.sciencedirect.com/science/article/pii/S0166354220302011.
    [Google Scholar]
  11. Slisco A, 2020. Anti-parasite Drug Used since 1980s May Help Stop Coronavirus, New Study Says. Newsweek. April, 04. Available at: https://www.newsweek.com/anti-parasite-drug-used-since-1980s-may-help-stop-coronavirus-new-study-says-1496083. Accessed April 5, 2020.
    [Google Scholar]
  12. Chaccour C, Hammann F, Rabinovich NR, 2017. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J 16: 161.
    [Google Scholar]
  13. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC, 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 11221133.
    [Google Scholar]
  14. Yamasmith E et al., 2018. Efficacy and Safety of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind, Placebo-controlled Trial. He 34th Annual Meeting the Royal College of Physicians of Thailand- ‘Internal Medicine and One Health’: Chonburi, Thailand. Registry. Available at: https://clinicaltrials.gov/ct2/show/NCT02045069. Accessed Aplri 5, 2020.
    [Google Scholar]
  15. Gautret P et al., 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Available at: https://www.sciencedirect.com/science/article/pii/S0924857920300996.
    [Google Scholar]
  16. Song S, Zhang D, Qian Z, Li T, Shen Y, Hongzh L, 2020. A Pilot Study of Hydroxychloroquine in Treatment of Patients with Common Coronavirus Disease-19 (COVID-19). Available at: http://subject.med.wanfangdata.com.cn/UpLoad/Files/202003/43f8625d4dc74e42bbcf24795de1c77c.pdf. Accessed April 5, 2020. Journal of Zhejiang University, 3.
    [Google Scholar]
  17. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, 2020 No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Méd Mal Infect 9: S0399-077X(20)30085-8.
    [Google Scholar]
  18. Scherr N, Pluschke G, Thompson CJ, Ramon-Garcia S, 2015. Selamectin is the avermectin with the best potential for buruli ulcer treatment. PLoS Negl Trop Dis 9: e0003996.
    [Google Scholar]
  19. Menez C, Sutra JF, Prichard R, Lespine A, 2012. Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity. PLoS Negl Trop Dis 6: e1883.
    [Google Scholar]
  20. Varatharaj A, Galea I, 2017. The blood-brain barrier in systemic inflammation. Brain Behav Immun 60: 112.
    [Google Scholar]
  21. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B, 2020. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology. Available at: https://pubs.rsna.org/doi/pdf/10.1148/radiol.2020201187.
    [Google Scholar]
  22. Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS, 2012. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 56: 54095413.
    [Google Scholar]
  23. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J, 1999. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57: 11471152.
    [Google Scholar]
  24. Chandler RE, 2018. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg 98: 382388.
    [Google Scholar]
  25. Lespine A, Alvinerie M, Sutra JF, Pors I, Chartier C, 2005. Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat. Vet Parasitol 128: 251260.
    [Google Scholar]
  26. Chiu SH, Lu AY, 1989. Metabolism and tissue residues. Campbell WC, ed. Ivermectin and Abamectin. New York, NY: Springer-Verlag, 131143.
    [Google Scholar]
  27. Kalil AC, 2020. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. Available at: https://jamanetwork.com/journals/jama/fullarticle/2763802.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.20-0271
Loading
  • Received : 08 Apr 2020
  • Accepted : 10 Apr 2020
  • Published online : 16 Apr 2020
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error